Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple cancers and correlates with poor survival. We previously demonstrated in vivo safety of bifunctional (bi) shRNA STMN1 bilamellar invaginated vesicle (BIV) and that systemic delivery correlated with antitumor activity. Patients with superficial advanced refractory cancer with no other standard options were entered into trial. Study design involved dose escalation (four patients/cohort) using a modified Fibonacci schema starting at 0.7 mg DNA administered via single intratumoral injection. Biopsy at baseline, 24/48 hours and resection 8 days after injection provided tissue for determination of cleavage product using next-generation sequencing (NGS) and reverse transcription quantitative polymerase chain reaction (RTqPCR), 5′ RLM rapid amplification of cDNA ends (RACE) assay. Serum pharmacokinetics of circulating plasmid was done. Twelve patients were entered into three dose levels (0.7, 1.4, 7.0 mg DNA). No ≥ grade 3 toxic effects to drug were observed. Maximum circulating plasmid was detected at 30 seconds with less than 10% detectable in all subjects at 24 hours. No toxic effects were observed. Predicted cleavage product was detected by both NGS (n = 7/7 patients analyzed, cohorts 1, 2) and RLM RACE (n = 1/1 patients analyzed cohort 3). In conclusion, bi-shRNA STMN1 BIV is well tolerated and detection of mRNA target sequence-specific cleavage product confirmed bi-shRNA BIV mechanism of action.
INTRODUCTION
Stathmin 1 (STMN1), a protumorigenic protein, is a critical intermediate during signal transduction in modulation and control of microtubule depolymerization and interphase tubulin dimer/ polymer partitioning. The process of mitotic spindle formation is a coordinated, balanced interaction between the stabilizing activities of microtubule-associated proteins (XMAP215, EB1), motor proteins (predominantly kinesin, e.g., , and plus-end depolymerases including XKCM1, MCAK, and STMN1. 1 A tightly regulated sequenced pattern of STMN1 phosphorylation and dephosphorylation is necessary for entry into prophase and, terminally, into cytokinesis, respectively. 2, 3 These functions are critical for malignant cell survival. 4 STMN1 is highly expressed in a variety of human malignancies, [5] [6] [7] and has been shown to be upregulated in multiple cancers. [8] [9] [10] [11] Moreover, upregulated stathmin has been shown to be significantly correlated with poor survival. [11] [12] [13] High STMN1 expression negatively influences response to microtubule targeting drugs. 14, 15 Knockdown of malignant cell STMN1 expression results in an increase in the G2M phase cell population, an inhibition of clonogenicity, and a marked increase in apoptosis. 6, 16, 17 Furthermore, RNAi-mediated STMN1 knockdown inhibits tumor proliferation and cancer cell invasion in both A549 and H1299 NSCLC lines in vitro 18 and tumor growth of MKN-45 gastric cancer in vivo. 19 We previously demonstrated >90% knockdown of STMN1 protein with bi-shRNA STMN1 bilamellar invaginated vesicle (BIV) in comparison to control which correlated in vitro (CCL-247 and SK-Mel-28) and in vivo (CCL-247) with tumor cell death and nodule regression, respectively. 20, 21 Similar results with bi-shRNA BIV therapeutics to other molecular targets have also been demonstrated. 22 Toxicology and biodistribution studies in biorelevant rats and mice predict a high expectation of safety in cancer patients thereby justifying phase 1 study. 21, 23 The bi-shRNA technology has previously been utilized to silence furin expression and consequent TGFβ isoform activation as part of a novel immune modulatory therapeutic, FANG vaccine, now progressing through a series of phase 2 trials. [24] [25] [26] Clinical results demonstrate 90-95% TGFβ1 and β2 knockdown.
The delivery mechanism of the bi-shRNA STMN1 vector comprises a 1, 2-dioleoyl-3-trimethylammonium propane and cholesterol liposome. [27] [28] [29] [30] This is a manually extruded formulation which forms BIV's, which encapsulate the nucleic acid STMN1 vector thereby forming a fusogenic therapeutic nanolipoplex. Clinical safety and efficacy of these BIVs for DNA vector delivery has been demonstrated in several clinical trials. 23, 29 Specifically, DNA delivery following systemic administration to target organ/ tissue sites and functionality were demonstrated. 23, 30 We seek 
RESULTS
Twelve patients received one IT injection of bi-shRNA STMN1 BIV and all 12 were evaluable for safety, verification of mechanism, and determination of-response. Demographics of these patients are shown in Table 1 .
Safety
No grade ≥ 3 drug-related toxic effects were observed. Toxic effects which were possibly or definitely related to bi-shRNA STMN1 BIV are shown in Table 2 . Four grade < 3 events were interpreted as nonrelated events. These included cellulitis (not at injection site), hypokalemia, superior vena cava syndrome (related to cancer), and cerebral hemorrhage (related to cancer metastasis) within 30 days of study treatment.
Response
Patient response at month 1 and survival are shown in Table 3 . Twenty percent tumor necrosis on day 8 in comparison to 0% necrosis at baseline was noted in patient 1009.
Pharmacokinetics
Total DNA was extracted from whole blood on all 12 patients at defined time points and analyzed by qPCR. All patients had significant amount of plasmids in the circulation (Figure 1a) , one patient with angiosarcoma (a highly vascular solid tumor) had higher circulating copies of STMN1 DNA at 1.33 × 10 9 copies per 100 µl of blood (Figure 1a, patient #1002 ). The highest copies of circulating plasmids detected for other patients ranged from 7.15 × 10 5 (Figure 1a , patient #1004) to 1.51 × 10 8 (Figure 1a , patient #1009) per 100 µl of blood. Typically, PK showed circulating plasmids dropping to less than 10% of the highest copies detected within 5 minutes (patient #1007, Figure 1b,c; patient #1009, Figure 1c) . A few patients showed longer initial circulating half-lives (patients # 1009 and #1010, Figure 1c) ; however, in all cases plasmid concentrations decline to less than 10% within 24 hours (Figure 1c) and less than 0.1% after 7-8 days (data not shown).
RNA interference mediated cleavage product detection mRNA target strand cleavage product was identified within the tumor mass on day 1 or 2 postinjection in three of the cohort 1 (patient #1002, 1004, and 1006) and all of the cohort 2 patients as per NGS method (Figure 2a) . The sample from patient #1005 did not yield sufficient material to pass the quality control used for NGS processing and was therefore not included in the run. For cohort 3, we first used the less sensitive method of gel-electrophoresis analysis to identify RLM-RACE product; the expected cleavage product was readily identified from cohort 3 patient #1013 (Figure 2b) . The identity of the RLM-RACE product was then sequence confirmed (Figure 2c) . Cohort 3 samples were not further analyzed by NGS. 
DISCUSSION
This study demonstrates the safety of intratumoral administration of bi-shRNA STMN1 BIV at dose levels between 0.7 and 2.0 mg pDNA. Furthermore, demonstration of circulating pDNA up to 1.3 × 10 9 copies per 100 ìl blood, with no evidence of concurrent or 30-day toxic effect, supports justification of i.v. administration starting at dosing levels calculated to produce the range of circulating plasmid levels herein documented. This study was not designed to evaluate tumor response, thus no conclusion regarding response to a single intratumoral injection can be reached. The focus of this evaluation was to verify bi-shRNA STMN1 mechanism of action as reflected in the detection of mRNA targeted sequence-specific cleavage product. These fragments are not normally expressed in biopsied tumor tissue as there is no natural RNAi cleavage to the designed STMN1 sequence site. Here, we demonstrate the bi-shRNA STMN1 specific cleavage product is found in all cohort 1 and 2 treated tissues examined with the highly sensitive NGS method. The NGS counts on the specific cleaved STMN1 mRNA varied widely from tissue to tissue possibly due to the varied abundance of tumor cells and inhomogeneity of STMN1 mRNA expression within the sampled tissue. For patient 1013 of cohort 3, the specific cleavage product was found in treated tissue one day after the treatment with a less sensitive RLM-RACE method.
The RT-qPCR method also demonstrated reduced target mRNA expression within the treated tissue samples further validating efficacy and specificity of the therapeutic agent. Our formulation appears to be safe within the pDNA range detected in circulation; the highest detected pDNA at 1.3 × 10 9 copies pDNA per 100 µl is equivalent to 0.004 mg/kg in an average 70 kg person. Within the dose range used in this study, we were able to readily demonstrate one of the mechanisms of drug action (target mRNA cleavage) and the result of drug treatment at molecular level (reduction of target mRNA). mRNA PK showed that the target mRNA was effectively reduced within 1-2 days after the treatment and then back to a normal level after 7-8 days post-treatment, this is very similar to what we observed in vitro. 20 To achieve clinical effectiveness, we believe the treatment schedule will need to be dosed two times per week in order to continuously silence target gene expression as the intended therapeutic effect. The other mechanisms of action of bi-shRNA, i.e., p-body sequestration, noncleavage dependent DNA degradation and inhibition of translation, 20 were not evaluated. A variety of target specific anti-stathmin effectors including ribozymes 32 and si-RNA 6, 16 have been used to silence STMN1 in vitro 2, 16, 32 and, additionally, in combination with chemotherapeutic agents where additive to synergistic interactions have been demonstrated, but prior to this report no evidence of cleavage product confirmation has been demonstrated. [33] [34] [35] Previously, we have described bi-shRNA STMN1 BIV cleavage product detection both in vitro and in vivo, but not in patients. 21 Data presented in this report are the first demonstration that STMN1 expression can be knocked down by RNAi approach in humans. Further clinical studies could advance this therapeutic modality into an effective cancer therapeutic agent either as stand alone or in combination with chemotherapeutic agents. Constitutively expressed shRNA using a pol II promoter on a miR-30 backbone mimics a pri-miRNA and potentially provides an advantage over synthetic siRNA by utilizing the full array of the endogenous miRNA biogenic machinery. Using an adapted stem-loop reverse transcription-polymerase chain reaction RT-PCR method, 36 we previously confirmed the presence of the predicted guide strand in vivo. 20 We were able to 20 amplify the guide strand sequence from RNA isolated from cells transfected with either bi-shRNA STMN1 or siRNA STMN1 . Studies on the synthesis and maturation of miRNAs provided guidance on the design of shRNA. [37] [38] [39] With respect to delivery other liposomes are routinely transported into target cells by clathrin-mediated endocytosis and/or macropinocytosis, processes resulting in low efficiency of endosome release into the cytoplasm. 40, 41 In contradistinction, the fusogenic BIVs utilized here bypass endosomal/lyzosomal encapsulation thereby allowing for more effective intracellular delivery. In addition, avoiding the use of double-stranded RNA moieties (siRNA and shRNA, respectively) and bypassing endosome transport (with exposure to Toll-like receptors (TLR)) minimizes the risk of interferon mediated off-target side effects (IFN-α and 2′-5′ OAS will be evaluated in the phase 1, 4 bi-shRNA STMN1 study).
In a comparison of the functional effectiveness of identical target strand-specific sequence bi-shRNA STMN1 to siRNA STMN1 in a HCT-116 growth inhibition assay, we generated dose response curves showing greater cell kill with the bishRNA STMN1. Although bi-shRNA superior effectiveness was shown throughout the full comparison dose range, the target specific cleavage product (5′ rapid amplification of cDNA ends (5′-RACE)) was detected at all siRNA STMN1 concentrations, but only at the higher dose of bi-shRNA STMN1. Thus, although cleavage product can be used as a measure of bi-shRNA STMN1function, the multiple mechanisms of bi-shRNA are not limited to just the RISC cleavage dependent component.
In conclusion, bi-shRNA STMN1 BIV is safe at low intratumoral injected dose levels achieving measurable serum plasmid levels out to 6 hours on the basis of which additional bi-shRNA STMN1 BIV testing has been initiated to explore safety and activity of intravenous delivery; the final results of which will be reported when completed. Importantly, we were able to 
MATERIALS AND METHODS
Inclusion criteria. All patients were treated at Mary Crowley Cancer Research Centers, Dallas, TX. Patients were eligible for inclusion in this study if they met the following key criteria: (i) histologically confirmed advanced and/or metastatic cancer; (ii) biopsy accessible lesion; (iii) subjects that have completed all acceptable therapies; (iv) age ≥18 years; (v) ECOG performance status (PS) 0-2; (vi) adequate organ and marrow function; (vii) signed IRB approved informed consent; and (viii) negative pregnancy test. Patients were excluded from this study for the following selected reasons: (i) cancer treatment within 3 weeks prior to entering the study; (ii) patients with known active brain metastases; and (iii) other medical disorders (Hepatitis B and C infection, human immunodeficiency virus, autoimmune disease).
Study design. This study design was (i) to determine single dose safety over 1 month, (ii) to obtain evidence of plasmid circulation, and (iii) to verify bi-shRNA mechanism via cleavage product detection. Patients were accrued in four-patient, dose-escalation cohorts using a modified Fibonacci schema (100%→50%→33%→33%) at a starting intratumoral dose of 0.7 mg (equivalent to 0.010 mg/kg in a 70 kg human) of DNA up to a dose of 2.0 mg (equivalent to 0.029 mg/kg in a 70 kg human) of DNA intratumoral/single dose. Patients enrolled into Cohort 1 were staggered. No patient received the study agent until the preceding subject received the first injection plus an additional week of follow up. The bi-shRNA STMN1 BIV was administered as described below (see Injection Technique). Tumor staging (by comprehensive computed tomography/magnetic resonance imaging scans) was performed at baseline and at end of treatment. Each patient was monitored closely for toxicity throughout the study. If one of four subjects within a dose cohort experienced a DLT, that dose cohort would be expanded to six patients provided no further subjects experienced a DLT. If no further subjects experienced a dose limiting toxicity (DLT), dose-escalation was allowed to continue. If ≥2 subjects within a dose cohort experienced a DLT, that would define the DLT dose level and the maximum tolerated dose would be designated the penultimate dose level.
Serum for pharmacokinetics (PK) was collected within 30 minutes prior to administration and at the following time points afterwards: ≤30 seconds (i.e., immediately after administration drawn from a separate site), 5 minutes, 30 minutes, 1 hour, 6 hours, 24 hours, 48 hours, and on day 8. One to 2 weeks prior to the treatment, a biopsy of the accessible lesion was obtained for reverse transcription quantitative polymerase chain reaction (RT-qPCR), 5′ RLM RACE (bi-shRNA STMN1 expression and target strand sequence specificity), next-generation sequencing (NGS), and plasmid baseline assays (bi-shRNA STMN1 delivery). Additionally, using a randomized approach, a biopsy of an accessible tumor lesion was obtained at 24 hours (± 2 hours) postinfusion in three patients and at 48 hours postinfusion in the remaining three patients for (including but not limited to) RT-qPCR (STMN1 mRNA expression), RLM 5′ RACE (bi-shRNA STMN1efficacy), NGS, and plasmid baseline assays (bi-shRNA STMN1 delivery) 30 and (if possible) stathmin protein assessment. The entire lesion was excised or incisionally biopsied on day 8, 7 days postadministration for immunohistochemistry, H&E, plasmid qPCR, RACE, NGS, and (if possible) stathmin protein assessment.
Lipoplex/DNA products in general may induce an inflammatory response. Therefore immediately prior to injection subjects were premedicated with oral dexamethasone (8 mg, 1 hour prior to injection), indocin (25 mg) and acetaminophen (650 mg). 31 The night before injection, subjects were premedicated with 8 mg of oral dexamethasone. All patients not already taking a proton pump inhibitor received rabeprazole sodium 20 mg po qd 24 hours prior to study drug and continuing for 5 days.
Injection technique.
In all patients, the longest diameter of the tumor was determined and trisected. At each of the two trisection points the needle was inserted perpendicular to the skin and a minimum of 0.5 ml of bi-shRNA STMN1 BIV injected into each site. The remainder of the volume (i.e., > 1 ml) was equally divided and injected by a fanning technique through each of the two individual injection sites. A Tegaderm dressing (3M Healthcare, St. Paul, MN) was adhered to the tumor/ injection site and the tumor, perpendicular diameter, and injection sites marked for biopsies. PK analysis. Blood samples were collected from patients at defined time points (baseline, within 0.5, 5, 30, 60 minutes, 6 hours, 1 and 2 days following injection) for PK analysis. The blood was collected in ethylenediaminetetraacetic acid tubes, aliquotted, and frozen until ready for analysis. Total DNA was extracted from 100 µl whole blood using the QiaAmp extraction kit (Qiagen, Valencia, CA). Extracted DNA was quantified by NanoDrop (Thermo Scientific, Wilmington, DE). Quantitative PCR was performed using reagents from Applied Biosystems and the Applied Biosystems 7900HT Fast Real-Time PCR instrument (Life Technologies, Grand Island, NY). Positive control bi-shRNA STMN1 plasmid DNA was used to generate standard curves and the patient samples were quantified relative to the standard. Each sample was tested in triplicate and the raw qPCR results (copies of bi-shRNA STMN1 plasmid) were normalized relative to the total yield of DNA extracted from each respective blood sample. DNA extraction and qPCR were done by GE/SeqWright (Houston, TX).
Tumor biopsies. Core needle biopsies were collected from enrolled patients at pretreatment, 24 or 48 hours, and 7 or 8 days after a single intratumoral injection. A core biopsy was divided into five parts: one part was embedded in neutral buffered formalin, two parts were stored in optimum cutting temperature compound medium, and the remaining two parts were submerged in a tube containing Allprotect tissue reagent Nucleic acid isolation from tumor biopsies. Total RNA was extracted from tumor biopsies for RLM-RACE assay. AllPrep DNA/RNA/Protein mini kit (Qiagen) was used to isolate DNA, RNA, and protein from the cohort 1 and 2 tumor biopsies. DNA/RNA/protein isolation was essentially done by following the procedures recommend by the manufacturer; briefly, 10-30 mg of tumor biopsies was homogenized in RLT buffer provided by the kit. The homogenate was then loaded onto an Allprep DNA spin column. The total DNA (including genomic DNA and plasmid DNA) was bound to the DNA spin column and was eluted using EB buffer. The flow-through after passing through the DNA spin column was precipitated using ethanol and then loaded to an RNeasy column. The total RNA bound to the RNeasy column was eluted in nuclease-free water. The flow-through after passing through the RNeasy column was precipitated using APP buffer and dissolved in 4% SDS buffer. The isolated total DNA and RNA were quantified using NanoDrop (Thermo Scientific). The integrity of total RNA was examined on a RNA chip using Experion automated electrophoresis system (Bio-Rad, Hercules, CA). In order to improve RNA extraction yield, 1 ml Trizol (Life Technologies) was used to homogenize 10-30 mg tumor biopsies of the third cohort. After centrifugation, the aqueous phase was precipitated using isopropanol. The isolated total RNA was then treated with DNase I (Qiagen) and cleaned-up using an RNeasy column (Qiagen). The isolated total RNA was quantified using Nanorop (Thermo Scientific). The integrity of total RNA was examined on a RNA chip using Experion automated electrophoresis system (Bio-Rad)
RLM-RACE.
Three to six micrograms of total RNA were ligated to 250 ng of an RNA adaptor at 37 °C for an hour. The ligated RNA was purified using Amicon Centrifugal Filter Unit (100 KDa) (Millipore, Billerica, MA) and was then applied to synthesize cDNA using STMN1-specific RT primer and a SuperScript III reverse transcriptase kit (Life Technologies). A portion of the synthesized cDNA was used as templates in a 50 µl of PCR amplification reaction primed with the RNA adaptor-specific primer and STMN-specific primers (Platinum Taq DNA polymerase kit, Life Technologies). An additional round of PCR with nested primers was performed to amplify the signals of site-specific STMN1 cleavage product. The PCR products were visualized on a 2% E-gel (Life Technologies). The band with predicted size was cut from the gel, purified using a QIAquick gelpurification kit (Qiagen) and sequence-confirmed.
NGS.
The nested-PCR products of RLM-RACE were analyzed using NGS performed by GE/SeqWright (Houston, TX). Briefly, the nested-PCR products were quantified using PicoGreen and quality-checked on an agarose gel. Pair-ended and coded libraries were generated for each sample using a TruSeq DNA sample preparation kit (Illumina, San Diego, CA). The libraries were then combined at equal molar ratios and sequenced on an Illumina MiSeq System with 2 × 250 bp read lengths. The sequencing run was spiked with 50% Phi X control to increase diversity and data quality. The Illumina MiSeq sequencing reads underwent alignment to human STMN1 transcript (GenBank accession number NM_203401) and were analyzed for predicted STMN1 cleavage site. Cutadapt (v 1.2.1) was used to trim off the RNA adaptor sequence (Martin M. 2011) and Tophat (v 2.0.6) was employed to align the trimmed reads against the reference sequence with perfect match.
